Members Trust Co Acquires 92 Shares of Eli Lilly and Company (NYSE:LLY)

Members Trust Co grew its holdings in Eli Lilly and Company (NYSE:LLY) by 28.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 410 shares of the company’s stock after purchasing an additional 92 shares during the period. Members Trust Co’s holdings in Eli Lilly and Company were worth $363,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Scarborough Advisors LLC grew its holdings in Eli Lilly and Company by 7.4% during the fourth quarter. Scarborough Advisors LLC now owns 465 shares of the company’s stock worth $271,000 after purchasing an additional 32 shares during the period. Richardson Financial Services Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $43,000. Warren Street Wealth Advisors LLC raised its stake in Eli Lilly and Company by 15.4% in the 4th quarter. Warren Street Wealth Advisors LLC now owns 964 shares of the company’s stock valued at $562,000 after acquiring an additional 129 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Eli Lilly and Company by 38.6% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 417,700 shares of the company’s stock valued at $243,486,000 after purchasing an additional 116,300 shares during the last quarter. Finally, Livelsberger Financial Advisory acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $135,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.9 %

Shares of Eli Lilly and Company stock traded down $17.48 during trading hours on Tuesday, reaching $912.03. The company’s stock had a trading volume of 1,454,833 shares, compared to its average volume of 2,994,412. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock’s fifty day simple moving average is $913.95 and its two-hundred day simple moving average is $854.46. The company has a market capitalization of $866.80 billion, a P/E ratio of 134.14, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a one year low of $547.61 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. On average, research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Barclays lifted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Truist Financial raised their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $979.29.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.